• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vera Therapeutics Stock In Focus As Kidney Trial Results Head To ASN Conference

    Simply Wall St·10/16/2026 11:40:29
    Listen to the news
    • Vera Therapeutics reported that in October 2026 it delivered five company sponsored abstracts at ASN Kidney Week, including a featured late breaking plenary on the final ORIGIN 3 efficacy analysis for TRUTAKNA in IgA nephropathy and interim PIONEER Phase 2 data across multiple glomerular diseases.
    • The concentration of late breaking TRUTAKNA and atacicept data in a single nephrology conference underscores how much Vera Therapeutics is tying its long term commercial ambitions and R&D spend to a single BAFF and APRIL focused platform in autoimmune kidney disease.
    • We will now look at how the investment narrative for Vera Therapeutics could be reshaped by the high profile ORIGIN 3 plenary spotlight.

    Scan for other kidney and autoimmune specialists that might be lining up their own late breaking data stories by reviewing the hand picked 34 healthcare AI stocks alongside Vera Therapeutics today.

    Vera Therapeutics Investment Narrative Recap

    To own Vera Therapeutics, you need to believe that TRUTAKNA can grow from an early IgA nephropathy launch into a broad autoimmune kidney platform while the firm manages losses tied to its commercial build out. The big near term catalyst is wider physician adoption backed by clinical data. The ASN plenary spotlight raises the profile of ORIGIN 3, but the core launch execution story does not change.

    The biggest operational risk is simple: uptake could trail expectations while an 82 person nephrology sales force and pipeline costs keep cash burn high. If prescription trends do not line up with earlier revenue forecasts that already saw trims, the path to profitability and justification for rich P/E assumptions becomes harder to support.

    The most relevant fresh item is Vera Therapeutics putting the final ORIGIN 3 efficacy analysis for TRUTAKNA into the opening ASN Kidney Week plenary, plus a late breaking poster. That is a prime forum for kidney specialists. The content directly ties to the key catalyst analysts have focused on, which is long term kidney function data that can reinforce confidence in BAFF and APRIL blockade.

    For you as a shareholder, the operational question is whether that visibility translates into more prescribing and stronger support from payers for a premium therapy in high risk IgA nephropathy. The PIONEER Phase 2 basket data in adult IgAN and pMN adds a secondary potential upside lever, since successful readouts in additional glomerular diseases could help Vera Therapeutics spread its fixed commercial and R&D spend over more indications.

    Vera Therapeutics' current analyst narrative points to forecast revenue of US$821.0 million and projected earnings of US$108.1 million by 2029. This implies yearly revenue growth from zero today and an earnings swing of about US$510 million, from a reported loss of US$401.9 million to positive earnings of US$108.1 million.

    Uncover why Vera Therapeutics' fair value indicates a 171% potential upside to its current price that could narrow quickly.

    NasdaqGM:VERA 1-Year Stock Price Chart
    NasdaqGM:VERA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view around Vera Therapeutics focuses less on ASN buzz and more on how fast TRUTAKNA moves toward full eGFR based approval. Before this conference was on the calendar, the most optimistic analysts were projecting about US$1.3b of revenue and US$397.6 million of earnings by 2029. That is a far more upbeat story than the consensus, and it shows how widely opinions already differ before this new data cycle lands. You can use those gaps as a prompt to explore several possible futures, rather than relying on a single forecast path.

    Explore 2 other Vera Therapeutics fair value estimates, including one that suggests as much as 1363% upside from the current price.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research.

    Looking For More Investment Ideas Beyond Vera Therapeutics?

    Once you have formed a view on Vera Therapeutics, it can help to set that opinion alongside other opportunities using the Simply Wall St Screener. That way you can compare risk, balance sheets and income potential across a wider watchlist instead of focusing on a single stock.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.